{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T03:33:09Z","timestamp":1773718389986,"version":"3.50.1"},"reference-count":54,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Clin Pathol"],"accepted":{"date-parts":[[2023,10,4]]},"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:p>Cancer testis antigen gene 1B (CTAG1B) and its associated gene product; New York oesophageal squamous carcinoma 1 (NY-ESO-1), represent a unique and promising target for cancer immunotherapy. As a member of the cancer testis antigen family (CTA), the protein\u2019s restricted expression pattern and ability to elicit spontaneous humoural and cellular immune responses has resulted in a plethora of novel modalities and approaches attempting to harness its immunotherapeutic anti-cancer potential. Here, we discuss the structure and function of CTAG1B\/NY-ESO-1 in both health and disease, immunohistochemical detection, as well as the most promising advances in the development of associated anti-cancer therapies. From cancer vaccines to engineered cellular therapy approaches, a multitude of immunotherapies targeting CTA\u2019s are coming to the forefront of oncology. Although the efficacy of such approaches have yet to provide convincing evidence of durable response, early phase clinical trial data has resulted in some exciting findings which will have significant potential to act as a platform for future practice changing technologies.<\/jats:p>","DOI":"10.1136\/jcp-2023-209053","type":"journal-article","created":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T13:27:56Z","timestamp":1697722076000},"page":"1-7","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Gene of the month: cancer testis antigen gene 1b (NY-ESO-1)"],"prefix":"10.1136","volume":"77","clinical-trial-number":[{"clinical-trial-number":"nct05620693","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01343043","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02319824","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03029273","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03709706","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01795976","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03691376","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01343043","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02609984","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00798629","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02775292","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02122861","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00299728","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01522820","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00292045","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01810016","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03358719","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00291473","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00090493","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03515551","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00616941","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00199849","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00112957","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01216696","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04526899","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03967223","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7182-0749","authenticated-orcid":false,"given":"Max","family":"Julve","sequence":"first","affiliation":[{"name":"Department of Surgery and Cancer, Imperial College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Kennedy","sequence":"additional","affiliation":[{"name":"Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1392-2755","authenticated-orcid":false,"given":"Adam Enver","family":"Frampton","sequence":"additional","affiliation":[{"name":"Department of Surgery and Cancer, Imperial College London, London, UK"},{"name":"Section of Oncology, Deptartment of Clinical and Experimental Medicine, FHMS, University of Surrey, Guildford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Izhar","family":"Bagwan","sequence":"additional","affiliation":[{"name":"Department of Cellular Pathology, Royal Surrey Hospital, Guildford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8952-7639","authenticated-orcid":false,"given":"Mark P","family":"Lythgoe","sequence":"additional","affiliation":[{"name":"Department of Surgery and Cancer, Imperial College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2023,10,19]]},"reference":[{"key":"2025092506210782000_77.1.1.1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2014.155"},{"key":"2025092506210782000_77.1.1.2","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00947","article-title":"NY-ESO-1 based Immunotherapy of cancer: Current perspectives","volume":"9","author":"Thomas","year":"2018","journal-title":"Front Immunol"},{"key":"2025092506210782000_77.1.1.3","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1669"},{"key":"2025092506210782000_77.1.1.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2011.02.001"},{"key":"2025092506210782000_77.1.1.5","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.5.1914"},{"key":"2025092506210782000_77.1.1.6","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.220413497"},{"key":"2025092506210782000_77.1.1.7","doi-asserted-by":"publisher","DOI":"10.1084\/jem.187.8.1349"},{"key":"2025092506210782000_77.1.1.8","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1159\/000134734","article-title":"Genomic cloning and localization of CTAG, a gene Encoding an Autoimmunogenic cancer-Testis antigen NY-ESO-1 to human Chromosome Xq28","volume":"79","author":"Chen","year":"1997","journal-title":"Cytogenet Genome Res"},{"key":"2025092506210782000_77.1.1.9","doi-asserted-by":"publisher","DOI":"10.1038\/nature03440"},{"key":"2025092506210782000_77.1.1.10","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-020-02306-y","article-title":"Unleashing the immune response to NY-ESO-1 cancer Testis antigen as a potential target for cancer Immunotherapy","volume":"18","author":"Raza","year":"2020","journal-title":"J Transl Med"},{"key":"2025092506210782000_77.1.1.11","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.20716"},{"key":"2025092506210782000_77.1.1.12","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/del494"},{"key":"2025092506210782000_77.1.1.13","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1097\/01.LAB.0000017169.26718.5F","article-title":"The cancer-Testis gene, NY-ESO-1, is expressed in normal fetal and adult Testes and in Spermatocytic Seminomas and Testicular carcinoma in situ","volume":"82","author":"Satie","year":"2002","journal-title":"Lab Invest"},{"key":"2025092506210782000_77.1.1.14","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.1282"},{"key":"2025092506210782000_77.1.1.15","doi-asserted-by":"publisher","DOI":"10.1038\/sj.emboj.7601235"},{"key":"2025092506210782000_77.1.1.16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083212","article-title":"Centrosomal Localisation of the cancer\/Testis (CT) antigens NY-ESO-1 and MAGE-C1 is regulated by Proteasome activity in tumour cells","volume":"8","author":"Pagotto","year":"2013","journal-title":"PLoS One"},{"key":"2025092506210782000_77.1.1.17","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-1882"},{"key":"2025092506210782000_77.1.1.18","article-title":"Expression of the cancer\/Testis antigen NY-ESO-1 in primary and metastatic malignant Melanoma (MM)--Correlation with Prognostic factors","volume":"7","author":"Velazquez","year":"2007","journal-title":"Cancer Immun"},{"key":"2025092506210782000_77.1.1.19","doi-asserted-by":"publisher","DOI":"10.1111\/his.13498"},{"key":"2025092506210782000_77.1.1.20","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-13-466","article-title":"Analysis of GAGE, NY-ESO-1 and Sp17 cancer\/Testis antigen expression in early stage non-small cell lung carcinoma","volume":"13","author":"Gjerstorff","year":"2013","journal-title":"BMC Cancer"},{"key":"2025092506210782000_77.1.1.21","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2013.0680"},{"key":"2025092506210782000_77.1.1.22","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2001.1974"},{"key":"2025092506210782000_77.1.1.23","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0703342104"},{"key":"2025092506210782000_77.1.1.24","doi-asserted-by":"crossref","first-page":"5209","DOI":"10.18632\/oncotarget.2101","article-title":"NY-ESO-1 as a potential Immunotherapeutic target in renal cell carcinoma","volume":"5","author":"Giesen","year":"2014","journal-title":"Oncotarget"},{"key":"2025092506210782000_77.1.1.25","first-page":"5125","article-title":"Diagnostic and therapeutic relevance of NY-ESO-1 expression in oral squamous cell carcinoma","volume":"29","author":"Ries","year":"2009","journal-title":"Anticancer Res"},{"key":"2025092506210782000_77.1.1.26","doi-asserted-by":"publisher","DOI":"10.1245\/ASO.2004.01.029"},{"key":"2025092506210782000_77.1.1.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2012.11.004"},{"key":"2025092506210782000_77.1.1.28","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/761378","article-title":"Increased NY-ESO-1 expression and reduced infiltrating Cd3+ T cells in cutaneous Melanoma","volume":"2015","author":"Giavina-Bianchi","year":"2015","journal-title":"J Immunol Res"},{"key":"2025092506210782000_77.1.1.29","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-1544"},{"key":"2025092506210782000_77.1.1.30","doi-asserted-by":"crossref","unstructured":"Teng MWL , Kershaw MH . Cancer Immunoediting. Cancer Immunotherapy 2013:85\u201399. doi:10.1016\/B978-0-12-394296-8.00007-5","DOI":"10.1016\/B978-0-12-394296-8.00007-5"},{"key":"2025092506210782000_77.1.1.31","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-1341"},{"key":"2025092506210782000_77.1.1.32","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002072","article-title":"Targeting cancer Testis antigens in Synovial sarcoma","volume":"9","author":"Mitchell","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025092506210782000_77.1.1.33","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.00686-12"},{"key":"2025092506210782000_77.1.1.34","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1038\/modpathol.2013.65","article-title":"NY-ESO-1 is a sensitive and specific immunohistochemical marker for Myxoid and round cell Liposarcomas among related Mesenchymal Myxoid Neoplasms","volume":"26","author":"Hemminger","year":"2013","journal-title":"Modern Pathology"},{"key":"2025092506210782000_77.1.1.35","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/cjp2.16","article-title":"Cancer\u2010Testis antigens PRAME and NY\u2010ESO\u20101 correlate with tumour grade and poor prognosis in Myxoid Liposarcoma","volume":"1","author":"Iura","year":"2015","journal-title":"J Pathol Clin Res"},{"key":"2025092506210782000_77.1.1.36","doi-asserted-by":"crossref","first-page":"44","DOI":"10.21037\/cco.2018.08.11","article-title":"NY-ESO-1: a promising cancer Testis antigen for sarcoma Immunotherapy and diagnosis","volume":"7","author":"Smith","year":"2018","journal-title":"Chin Clin Oncol"},{"key":"2025092506210782000_77.1.1.37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001294"},{"key":"2025092506210782000_77.1.1.38","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/ijc.34473","article-title":"The evidence base of US food and Drug Administration approvals of novel cancer therapies from 2000 to 2020","volume":"152","author":"Gloy","year":"2023","journal-title":"Int J Cancer"},{"key":"2025092506210782000_77.1.1.39","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-021-00346-0"},{"key":"2025092506210782000_77.1.1.40","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.220413497"},{"key":"2025092506210782000_77.1.1.41","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0403572101"},{"key":"2025092506210782000_77.1.1.42","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00008","article-title":"Vaccine strategies to improve anti-cancer cellular immune responses","volume":"10","author":"Vermaelen","year":"2019","journal-title":"Front Immunol"},{"key":"2025092506210782000_77.1.1.43","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000410","article-title":"Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk Resected Melanoma","volume":"8","author":"Cebon","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025092506210782000_77.1.1.44","doi-asserted-by":"crossref","first-page":"102405","DOI":"10.1016\/j.ctrv.2022.102405","article-title":"The paradigm shift in treatment from COVID-19 to oncology with mRNA vaccines","volume":"107","author":"Wei","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"2025092506210782000_77.1.1.45","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2537-9"},{"key":"2025092506210782000_77.1.1.46","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-32491-x","article-title":"Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with Synovial sarcoma","volume":"13","author":"Gyurdieva","year":"2022","journal-title":"Nat Commun"},{"key":"2025092506210782000_77.1.1.47","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/CCO.0000000000000843","article-title":"Immunotherapy of Sarcomas with modified T cells","volume":"34","author":"Mahalingam","year":"2022","journal-title":"Curr Opin Oncol"},{"key":"2025092506210782000_77.1.1.48","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.9.6116"},{"key":"2025092506210782000_77.1.1.49","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.2537"},{"key":"2025092506210782000_77.1.1.50","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2708"},{"key":"2025092506210782000_77.1.1.51","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-1417"},{"key":"2025092506210782000_77.1.1.52","doi-asserted-by":"publisher","DOI":"10.1016\/S0198-8859(01)00298-1"},{"key":"2025092506210782000_77.1.1.53","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.3366.3366","article-title":"Combination Immunotherapy with NY-ESO-1-specific CAR+ T cells with T-cell vaccine improves anti-myeloma effect","volume":"128","author":"Patel","year":"2016","journal-title":"Blood"},{"key":"2025092506210782000_77.1.1.54","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz253.134","article-title":"Trial in progress: first-in-human study of a novel anti-NY-ESO-1\u2013anti-Cd3, TCR-based Bispecific (Imcnyeso) as monotherapy in NY-ESO-1\/LAGE-1A-positive advanced solid tumours (Imcnyeso-101)","volume":"30","author":"Lopez","year":"2019","journal-title":"Annals of Oncology"}],"container-title":["Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jcp-2023-209053","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T13:21:19Z","timestamp":1758806479000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcp.bmj.com\/lookup\/doi\/10.1136\/jcp-2023-209053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,19]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12,14]]},"published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1136\/jcp-2023-209053"],"URL":"https:\/\/doi.org\/10.1136\/jcp-2023-209053","relation":{},"ISSN":["0021-9746","1472-4146"],"issn-type":[{"value":"0021-9746","type":"print"},{"value":"1472-4146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,19]]}}}